Clinical Trials Logo
  1. Home
  2. Retroperitoneal Sarcoma
  3. NCT05844813

Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal Sarcoma — NATARS  

Retroperitoneal Sarcoma Clinical Trial

Official title:
Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal Sarcoma-- A Nationwide Multicentered Prospective Controlled Study

Clinical Trial Summary

The goal of this clinical trial is to explore the potential survival benefits of neoadjuvant chemotherapy combined with target treatments followed by radical surgery in patients with primary high-risk/grade retroperitoneal sarcoma. The main questions it aims to answer are: - Whether the 1,3-year progression-free survival time(PFS) is prolonged in the neoadjuvant therapy group, compared with the surgery-only group. - The Overall survival time in the two groups. - The safety and tolerance in the neoadjuvant therapy group. Participants will be allocated into two groups once they meet the inclusion criteria. - Surgery-only Group: Patients will directly undergo surgeries after the confirmation of diagnosis through pre-operative biopsy. - Neoadjuvant therapy group: Patients will receive the neoadjuvant chemotherapy combined with target treatment for three circles before the following sarcoma resectional surgeries.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05844813
Study type Interventional
Source Peking University International Hospital
Contact
Status Enrolling by invitation
Phase Phase 4
Start date November 1, 2022
Completion date November 1, 2027
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03838718 - REtroperitoneal SArcoma Registry: an International Prospective Initiative
Terminated NCT00901836 - Preoperative Proton Radiotherapy for Retroperitoneal Sarcoma N/A
Completed NCT05044624 - Retroperıtoneal Soft-Tıssue Sarcomas N/A
Active, not recruiting NCT04189783 - Repeat or Single Quadratus Lumborum Block for the Reduction of Opioid Prescriptions After Surgery in Retroperitoneal Sarcoma Patients ("RESQU-SARC" Trial) Phase 2
Completed NCT04225494 - Perioperative Residual Adrenal Function After Extended Resection for Retroperitoneal Soft Tissue Sarcomas
Active, not recruiting NCT03792867 - Radical Resection and HIPEC for Recurrent Retroperitoneal Sarcoma N/A
Not yet recruiting NCT06025747 - Evaluation of Abemaciclib and Radiation Therapy Before Surgery for the Treatment of High-Risk Adipocytic Retroperitoneal Sarcoma Phase 1
Active, not recruiting NCT04224948 - The PET- Retroperitoneal Sarcoma Study N/A
Recruiting NCT04031677 - Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma Phase 3
Recruiting NCT05224934 - Preoperative Ultra-hypofractionated Radiotherapy Followed by Surgery for Retroperitoneal Sarcoma Phase 2
Completed NCT03877588 - Nutritional Status in Retroperitoneal Sarcoma. N/A
Completed NCT02384473 - Real-Time Contrast-Enhanced Ultrasonography and Shear Wave Elastography in Predicting Treatment Response in Patients With Soft Tissue Sarcoma Early Phase 1
Withdrawn NCT05302570 - Neoadjuvant Short-course Hypofractionated PBT for Non-metastatic RPS Phase 2
Recruiting NCT01659203 - Proton or Photon RT for Retroperitoneal Sarcomas Phase 1/Phase 2
Recruiting NCT05631379 - Influence of Nutritional Status on Oncologic and Operative Outcome in Patients Operated for Retroperitoneal Sarcoma
Recruiting NCT06327477 - Proton-Spatially Fractionated Radiotherapy and Standard Radiation Therapy for the Treatment of Newly Diagnosed Retroperitoneal Soft Tissue Sarcoma Phase 1/Phase 2